Discovery of Ro 41‐0960, a Non‐Steroidal Inhibitor of the Na + /K + ‐ATPase
ChemMedChem · 2026
DOI: 10.1002/cmdc.70442 ↗At a glance
Journal article in ChemMedChem, 2026. Written by Carlos Cruz-Cortés and 5 co-authors. Institution: Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA. Major MEDLINE topics: Sodium-Potassium-Exchanging ATPase, Enzyme Inhibitors, Drug Discovery. Cited 1 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY 4.0). Funded by: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (original language)
The Na + /K + ‐ATPase (NKA) is a central regulator of cardiac ion homeostasis and a validated target for heart failure. Yet, cardiotonic steroids used in clinical practice are limited by a narrow therapeutic window and pro‐arrhythmic effects. Here, we identify Ro 41‐0960 as a non‐steroidal inhibitor of NKA with a distinct mechanistic profile. The compound inhibits NKA activity with IC 50 values of 17.9 ± 1.1 µM for purified enzyme and 10.3 ± 1.1 µM in microsomal preparations. ATP‐dependent activity measurements revealed a non‐monotonic response in which inhibition was most pronounced at ATP concentrations below 4 mM and diminished at the highest ATP concentrations tested. Docking and molecular dynamics simulations suggest that Ro 41‐0960 can access both the cardiotonic steroid‐binding pocket and the nucleotide‐binding site; however, the ATP‐dependence data are not consistent with a simple ATP‐competitive mechanism. Furthermore, the compound shows only weak inhibition of SERCA (IC 50 > 100 µM) and does not alter electrophysiological parameters in human iPSC‐derived cardiomyocytes at concentrations producing near‐maximal NKA inhibition, providing initial evidence of a favorable cardiac safety profile. Together, these findings identify Ro 41‐0960 as an NKA inhibitor with a distinct chemical scaffold and provide a framework for the development of non‐steroidal NKA modulators.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Center for Arrhythmia Research, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Cell and Molecular Physiology, Loyola University Chicago, Maywood, Illinois, USA.
- Department of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, Texas, USA.
- Frankel Cardiovascular Center, Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
ORCID profiles: Eric N Jimenez-Vazquez, L Michel Espinoza-Fonseca
Funding
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Cite
APA
Cruz-Cortés, C., Šeflová, J., Guerrero-Serna, G., Jimenez-Vazquez, E. N., Anumonwo, J., & Espinoza-Fonseca, L. M. (2026). Discovery of Ro 41‐0960, a Non‐Steroidal Inhibitor of the Na + /K + ‐ATPase. ChemMedChem. https://doi.org/10.1002/cmdc.70442
Vancouver
Cruz-Cortés C, Šeflová J, Guerrero-Serna G, Jimenez-Vazquez EN, Anumonwo J, Espinoza-Fonseca LM. Discovery of Ro 41‐0960, a Non‐Steroidal Inhibitor of the Na + /K + ‐ATPase. ChemMedChem. 2026. doi:10.1002/cmdc.70442
BibTeX
@article{CruzCorts2026,
author = {Cruz-Cortés, Carlos and Šeflová, Jaroslava and Guerrero-Serna, Guadalupe and Jimenez-Vazquez, Eric N and Anumonwo, Justus and Espinoza-Fonseca, L Michel},
title = {Discovery of Ro 41‐0960, a Non‐Steroidal Inhibitor of the Na + /K + ‐ATPase},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.70442}
}
EUVIMED